GS protein-coupled adenosine receptor signaling and lytic function of activated NK cells

Journal of Immunology

Volumn 175, Issue 7, 2005, Pages 4383-4391

  Raskovalova, Tatiana ^a   Huang, Xiaojun ^a   Sitkovsky, Michail ^c   Zacharia, Lefteris C ^b   Jackson, Edwin K ^b   Gorelik, Elieser ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLOROADENOSINE; 2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; ADENOSINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE RECEPTOR STIMULATING AGENT; CYCLIC AMP; G PROTEIN COUPLED RECEPTOR; INTERLEUKIN 2;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; GENE DISRUPTION; LEWIS CARCINOMA; LYMPHOKINE ACTIVATED KILLER CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SARCOMA;

EID: 25444513372     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.7.4383     Document Type: Article

References (26)

1. Burnstock, G. 1997. The past, present and future of purine nucleotides as signalling molecules. Neuropharmacology 36: 1127-1139.
2. Klinger, M., M. Freissmuth, and C. Nanoff. 2002. Adenosine receptors: G protein-mediated signalling and the role of accessory proteins. Cell. Signal. 14: 99-108.
3. Cronstein, B. N. 1994. Adenosine, an endogenous anti-inflammatory agent. J. Appl. Physiol 76: 5-13.
4. Hasko, G., and B. N. Cronstein. 2004. Adenosine: an endogenous regulator of innate immunity. Trends Immunol. 25: 33-39.
5. Sitkovsky, M. V., D. Lukashev, S. Apasov, H. Kojima, M. Koshiba, C. Caldwell, A. Ohta, and M. Thiel. 2004. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu. Rev. Immunol. 22: 657-682.
6. Ohta, A., and M. Sitkovsky. 2001. Role of G-protein-coupled adenosine receptors in downregulalion of inflammation and protection from tissue damage. Nature 414: 916-920.
7. 2A adenosine receptor as a physiological immunosuppressor and to engineer inflammation in vivo. Biochem. Pharmacol. 65: 493-501.
8. Cronstein, B. N., D. Naime, and E. Ostad. 1994. The antiinflammatory effects of methotrexate are mediated by adenosine. Adv. Exp. Med. Biol. 370: 411-416.
9. Cronstein, B. N., M. C. Montesinos, and G. Weissmann. 1999. Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFκB. Proc. Natl. Acad. Sci. USA 96: 6377-6381.
10. Blay, J., T. D. White, and D. W. Hoskin. 1997. The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res. 57: 2602-2605.
11. Koshiba, M., H. Kojima, S. Huang, S. Apasov, and M. V. Sitkovsky. 1997. Memory of extracellular adenosine A2A purinergic receptor-mediated signaling in murine T cells. J. Biol. Chem. 272: 25881-25889.
12. Huang, S., S. Apasov, M. Koshiba, and M. Sitkovsky. 1997. Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood 90: 1600-1610.
13. Hoskin, D. W., J. J. Butler, D. Drapeau, S. M. Haeryfar, and J. Blay. 2002. Adenosine acts through an A3 receptor to prevent the induction of murine anti-CD3-activated killer T cells. Int. J. Cancer 99: 386-395.
14. Hoskin, D. W., T. Reynolds, and J. Blay. 1994. 2-Chloroadenosine inhibits the MHC-unrestricted cytolytic activity of anti-CD3-activated killer cells: evidence for the involvement of a non-A1/A2 cell-surface adenosine receptor. Cell. Immunol. 159: 85-93.
15. Johansson, B., L. Halldner, T. V. Dunwiddie, S. A. Masino, W. Poelchen, L. Gimenez-Llort, R. M. Escorihuela, A. Fernandez-Teruel, Z. Wiesenfeld-Hallin, X. J. Xu, et al. 2001. Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor. Proc. Natl. Acad. Sci. USA 98: 9407-9412.
16. Ledent, C., J. M. Vaugeois, S. N. Schiffmann, T. Pedrazzini, M. El Yacoubi, J. J. Vanderhaeghen, J. Costentin, J. K. Heath, G. Vassart, and M. Parmentier. 1997. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature 388: 674-678.
17. 3 adenosine receptor gene in mice and its effect on stimulated inflammatory cells. J. Biol. Chem. 275; 4429-4434.
18. Rosenberg, S. A., and M. T. Lotze. 1986. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Annu. Rev. Immunol 4: 681-709.
19. Rosenberg, S. A., M. T. Lotze, and J. J. Mule. 1988. NIH conference: new approaches to the immunotherapy of cancer using interleukin-2. Ann. Intern. Med. 108: 853-864.
20. Gunji, Y., N. L. Vujanovic, J. C. Hiserodt, R. B. Herberman, and E. Gorelik. 1989. Generation and characterization of purified adherent lymphokine-activated killer cells in mice. J. Immunol. 142: 1748-1754.
21. Peppoloni, S., R. B. Herberman, and E. Gorelik. 1985. Induction of highly immunogenic variants of Lewis lung carcinoma tumor by ultraviolet irradiation. Cancer Res. 45; 2560-2566.
22. Namiki, A., E. Brogi, M. Kearney, E. A. Kim, T. Wu, T. Couffinhal, L. Varticovski, and J. M. Isner. 1995. Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells. J. Biol. Chem. 270: 31189-31195.
23. Jackson, E. K., Z. Mi, M. T. Koehler, J. A. Carcillo, Jr., and W. A. Herzer. 1996. Injured erythrocytes release adenosine deaminase into the circulation. J. Pharmacol Exp. Ther. 279: 1250-1260.
24. Kagi, D., B. Ledermann, K. Burki, P. Seiler, B. Odermatt, K. J. Olsen, E. R. Podack, R. M. Zinkernagel, and H. Hengartner. 1994. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 369: 31-37.
25. Screpanti, V., R. P. Wallin, A. Grandien, and H. G. Ljunggren. 2005. Impact of FASL-induced apoptosis in the elimination of tumor cells by NK cells. Mol. Immunol. 42: 495-499.
26. Liu, C. C., C. M. Walsh, N. Eto, W. R. Clark, and J. D. Young. 1995. Morphologic and functional characterization of perforin-deficient lymphokine-activated killer cells. J. Immunol. 155: 602-608.